ArticleJournal of psychopharmacology (Oxford, England)2021
Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.
Article in Journal of psychopharmacology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Delta-9-tetrahydrocannabinol detection times using mass spectroscopy in oral fluid: a systematic review using a 5 ng/mL cut-off value.International journal of legal medicine · 2026Pooled it
- High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies.The American journal of psychiatry · 2025Pooled it
- Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review.The international journal of neuropsychopharmacology · 2025Pooled it
- Dose-Dependent Effects of Cannabis Edibles on Simulated Driving Performance: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Impact of Cannabis Edibles Combined With Alcohol on Driving, Field Sobriety Performance, and Subjective Effects: A Within-Participant Crossover Trial.JAMA network open · 2026Trial
- Effect of caffeine and cannabidiol (CBD) co-administration on Δ9-tetrahydrocannabinol (Δ9-THC) subjective effects, performance impairment, and pharmacokinetics.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Trial
- Detection of ΔDrug testing and analysis · 2024Trial
- Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.Psychopharmacology · 2024Trial
- Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial.Scientific reports · 2024Trial
- Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.Drug and alcohol dependence · 2024Trial
- A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance.CNS drugs · 2023Trial
- Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses.Psychopharmacology · 2023Trial
- Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.Journal of analytical toxicology · 2022Trial
- Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Co-use of cannabis and tobacco in the same occasion: Acute effects. A systematic review.Psychopharmacology · 2026Review
- The monoterpenes ⍺-pinene and limonene augment or mitigate THC-induced impairments in sustained attention in rats.Psychopharmacology · 2026Article
- Perceptions of Cannabis Vaping Advertising Messages and Warnings Among US Young Adults.Substance use & addiction journal · 2026Article
- Safety of Co-Administered Cannabidiol (CBD) and alcohol: a Phase I study.Journal of cannabis research · 2026Article
- Behavioral and Self-Report Cognitive Impairment Differences between Fast-Acting, Standard, and Placebo Cannabis Edibles.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCannabis legalization is expanding, but there are no established methods for detecting cannabis impairment.
aimCharacterize the acute impairing effects of oral and vaporized cannabis using various performance tests.
methodsParticipants (
resultsLow oral/vaporized doses did not impair cognitive/psychomotor performance relative to placebo but produced positive subjective effects. High oral/vaporized doses impaired cognitive/psychomotor performance and increased positive and negative subjective effects. The DRUID
conclusionsStandard approaches for identifying impairment due to cannabis exposure (i.e. blood THC and field sobriety tests) have severe limitations. There is a need to identify novel biomarkers of cannabis exposure and/or behavioral tests like the DRUID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.